BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30879840)

  • 1. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
    Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
    Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
    Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.
    Brendel J; Peukert S
    Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):273-87. PubMed ID: 15326917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
    Lagrutta A; Wang J; Fermini B; Salata JJ
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
    Guo X; Chen W; Sun H; You Q
    Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revealing kinetics and state-dependent binding properties of I
    Ellinwood N; Dobrev D; Morotti S; Grandi E
    Chaos; 2017 Sep; 27(9):093918. PubMed ID: 28964116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.
    Baczko I; Liknes D; Yang W; Hamming KC; Searle G; Jaeger K; Husti Z; Juhasz V; Klausz G; Pap R; Saghy L; Varro A; Dolinsky V; Wang S; Rauniyar V; Hall D; Dyck JR; Light PE
    Br J Pharmacol; 2014 Jan; 171(1):92-106. PubMed ID: 24102184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
    Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
    J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology.
    Bilodeau MT; Trotter BW
    Curr Top Med Chem; 2009; 9(5):436-51. PubMed ID: 19519460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.
    Ford J; Milnes J; Wettwer E; Christ T; Rogers M; Sutton K; Madge D; Virag L; Jost N; Horvath Z; Matschke K; Varro A; Ravens U
    J Cardiovasc Pharmacol; 2013 May; 61(5):408-15. PubMed ID: 23364608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
    Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
    Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
    Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
    Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
    Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
    J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of hesperetin on Kv1.5 potassium channels stably expressed in HEK 293 cells and ultra-rapid delayed rectifier K(+) current in human atrial myocytes.
    Wang H; Wang HF; Wang C; Chen YF; Ma R; Xiang JZ; Du XL; Tang Q
    Eur J Pharmacol; 2016 Oct; 789():98-108. PubMed ID: 27397430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.
    Olsson RI; Jacobson I; Iliefski T; Boström J; Davidsson Ö; Fjellström O; Björe A; Olsson C; Sundell J; Gran U; Gyll J; Malmberg J; Hidestål O; Emtenäs H; Svensson T; Yuan ZQ; Strandlund G; Åstrand A; Lindhardt E; Linhardt G; Forsström E; Högberg Å; Persson F; Andersson B; Rönnborg A; Löfberg B
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1269-73. PubMed ID: 24513046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5.
    Schumacher SM; McEwen DP; Zhang L; Arendt KL; Van Genderen KM; Martens JR
    Circ Res; 2009 Jun; 104(12):1390-8. PubMed ID: 19443837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.
    Fedida D; Eldstrom J; Hesketh JC; Lamorgese M; Castel L; Steele DF; Van Wagoner DR
    Circ Res; 2003 Oct; 93(8):744-51. PubMed ID: 14500335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.